BIOMAT Database Logo BIOMAT Database Logo

Combinations of 6-mercaptopurine (NSC-755) and 6-(methylmercapto)purine ribonucleoside (NSC-40774) in therapy of Ehrlich ascites carcinoma. 1967

M C Wang, and A I Simpson, and A R Paterson

UI MeSH Term Description Entries
D002286 Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms. Ehrlich Ascites Tumor,Ascites Tumor, Ehrlich,Ehrlich Tumor Carcinoma,Tumor, Ehrlich Ascites
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000963 Antimetabolites Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) Antimetabolite
D015122 Mercaptopurine An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. 6-Mercaptopurine,1,7-Dihydro-6H-purine-6-thione,6-Mercaptopurine Monohydrate,6-Thiohypoxanthine,6-Thiopurine,6H-Purine-6-thione, 1,7-dihydro-,BW 57-323H,Leupurin,Mecaptopurine Anhydrous,Mercaptopurina Wellcome,Puri-Nethol,Purimethol,Purinethol,6 Mercaptopurine,6 Mercaptopurine Monohydrate,6 Thiohypoxanthine,6 Thiopurine,BW 57 323H,BW 57323H
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

M C Wang, and A I Simpson, and A R Paterson
Chemotherapy of leukemia L1210 by 6-mercaptopurine (NSC-755) in combination with 6-methylthiopurine ribonucleoside (NSC-40774).
June 1967, Cancer chemotherapy reports,
M C Wang, and A I Simpson, and A R Paterson
Combination chemotherapy: treatment of the Ehrlich ascites carcinoma and several drug-resistant sublines with combinations of 6-mercaptopurine and 6-(methylmercapto)purine ribonucleoside.
January 1970, Canadian journal of biochemistry,
M C Wang, and A I Simpson, and A R Paterson
Phosphorylation of adenosine and deoxyadenosine in Ehrlich ascites carcinoma cells resistant to 6-(Methylmercapto)purine ribonucleoside.
April 1972, Canadian journal of biochemistry,
M C Wang, and A I Simpson, and A R Paterson
METABOLISM OF 6-MERCAPTOPURINE RIBONUCLEOSIDE BY EHRLICH ASCITES CARCINOMA CELLS.
October 1964, Canadian journal of biochemistry,
M C Wang, and A I Simpson, and A R Paterson
Studies of combination 6-mercaptopurine (NSC-755) and 6-methylmercaptopurine riboside (NSC-40774) in patients with acute leukemia and metastatic cancer.
February 1968, Cancer chemotherapy reports,
M C Wang, and A I Simpson, and A R Paterson
COMPARATIVE CLINICAL TOXICITY OF 6-MERCAPTOPURINE (NSC-755)-1 AND 6-MERCAPTOPURINE RIBONUCLEOSIDE (NSC-4911)-2 ADMINISTERED INTRAVENOUSLY TO PATIENTS WITH ADVANCED CANCER.
March 1964, Cancer chemotherapy reports,
M C Wang, and A I Simpson, and A R Paterson
Drug trials in neuroblastoma: cyclophosphamide (NSC-26271) alone; vincristine (NSC-67574) plus cyclophosphamide; 6-mercaptopurine (NSC-755) plus 6-methylmercaptopurine riboside (NSC-40774); and cytosine arabinoside (NSC-63878) alone.
January 1974, Cancer chemotherapy reports,
M C Wang, and A I Simpson, and A R Paterson
Mechanism of the growth inhibition potentiation arising from combination of 6-mercaptopurine with 6-(methylmercapto)purine ribonucleoside.
September 1970, Cancer research,
M C Wang, and A I Simpson, and A R Paterson
The enzymic formation of 6-(methylmercapto)purine ribonucleoside 5'-phosphate.
February 1966, Canadian journal of biochemistry,
M C Wang, and A I Simpson, and A R Paterson
Combination chemotherapy: synergistic inhibition of lymphoma L5178Y cells in culture and in vivo with 6-mercaptopurine and 6-(methylmercapto)purine ribonucleoside.
March 1969, Cancer research,
Copied contents to your clipboard!